Institutional members access full text with Ovid®

Share this article on:

Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Dave, Maneesh MBBS, MPH*; Mehta, Kathan MBBS, MPH; Luther, Jay MD; Baruah, Anushka MBBS§; Dietz, Allan B. PhD; Faubion, William A. Jr MD

doi: 10.1097/MIB.0000000000000543
Clinical Review Articles

Abstract: Recent advances in inflammatory bowel disease (IBD) therapeutics include novel medical, surgical, and endoscopic treatments. Among these, stem cell therapy is still in its infancy, although multiple studies suggest that the immunomodulatory effect of stem cell therapy may reduce inflammation and tissue injury in patients with IBD. This review discusses the novel avenue of stem cell therapy and its potential role in the management of ulcerative colitis and Crohn's disease. We conducted a comprehensive literature search to identify studies examining the role of stem cell therapy (without conditioning and immunomodulatory regimens) in IBD. Taken together, these studies suggest a promising role for stem cell therapy in IBD although the substantial challenges, such as cost and inadequate/incomplete characterization of effect, limit their current use in clinical practice.

Article first published online 30 July 2015.Supplemental Digital Content is Available in the Text.

*Division of Gastroenterology and Liver Disease, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, Ohio;

Division of Internal Medicine, University of Pittsburgh Medical Centre Shadyside Hospital, Pittsburgh, Pennsylvania;

Division of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, Massachusetts;

§Division of Internal Medicine, John Stroger Hospital of Cook County, Chicago, Illinois;

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; and

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.

Reprints: Maneesh Dave, MBBS, MPH, Division of Gastroenterology and Liver Disease, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH 44106 (e-mail:; and William A. Faubion, Jr, MD, Division of Gastroenterology and Hepatology, Guggenheim 10, 200 1st St. SW, Rochester, MN 55905 (e-mail:

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (

W. A. Faubion's laboratory is supported by National Institutes of Health grants R01 AI089714.

The authors have no conflict of interest to disclose.

Received May 7, 2015

Accepted June 17, 2015

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website